Opinion|Videos|December 23, 2024
Long-Term Cognitive Effects of Cladribine: SDMT Score Changes in the CLARIFY-MS Extension Study
Author(s)Gabriel Pardo, MD, FAAN, Martin Belkin, DO
Key Takeaways
- Fingolimod, siponimod, and natalizumab can penetrate the blood-brain barrier, potentially impacting brain health directly.
- The impact of DMTs on cognitive health is under investigation, with some evidence suggesting benefits in slowing cognitive decline.
Panelists discuss how the CLARIFY-MS extension study revealed stable cognitive function 4 years post cladribine, highlighting the potential of early treatment to preserve cognitive capabilities in multiple sclerosis (MS) patients. Cognitive assessments remain crucial for monitoring disease progression and tailoring patient management.
Advertisement
Video content above is prompted by the following:
- Cognition data was examined in the CLARIFY-MS extension study in patients 4 years after initial dose of cladribine. Please discuss changes in Symbol Digit Modalities Test (SDMT) scores over time and what these results mean for the cognitive function of the patient.
- What are your impressions of long-term cognition data with other high-efficacy therapies?
- How do you utilize cognitive data in your practice?
Advertisement
Related to this article
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
In a 16-person placebo-controlled trial, every cognitively unimpaired adult given AV-1959R developed anti-amyloid-beta antibodies, while placebo recipients stayed at baseline.
Newly presented post hoc analyses examined diazepam nasal spray for status epilepticus in seizure clusters and intervals between clusters in children, alongside real-world data on rescue medication prescribing.
A retrospective 10-center U.S. study found stiripentol reduced convulsive seizure frequency, status epilepticus episodes, and emergency health care use in patients with Dravet syndrome.
A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.
Here's some of what is coming soon to NeurologyLive® this week.
Ocrelizumab demonstrated noninferiority to fingolimod for relapse control but displayed greater reductions in MRI lesion activity among pediatric patients with relapsing-remitting multiple sclerosis.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is biomarkers in multiple sclerosis!
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ocrelizumab Shows MRI Benefits vs Fingolimod in Phase 3 Pediatric-Onset Multiple Sclerosis Study
2
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
3
TSHA-102 Produces Multidomain Functional Gains in Rett Syndrome
4
First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy
5